Related Experiment Video
Updated: Jun 11, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Comparing predictors of conversion and decline in mild cognitive impairment
S M Landau1, D Harvey, C M Madison
1Helen Wills Neuroscience Institute, University of California, Berkeley 94720-3190, USA. slandau@berkeley.edu
Neurology
|July 2, 2010
Summary
Predicting Alzheimer's disease (AD) progression in mild cognitive impairment (MCI) is crucial. Combined FDG-PET scans and episodic memory tests effectively predict conversion to AD, aiding early intervention strategies.
Area of Science:
- Neurology
- Biomarker Research
- Neuroimaging
Background:
- Mild cognitive impairment (MCI) is a precursor to Alzheimer's disease (AD).
- Identifying reliable predictors of MCI progression to AD is essential for timely intervention.
- Current markers for predicting disease progression in MCI are not fully established.
Purpose of the Study:
- To evaluate the prognostic capabilities of various measurements in predicting MCI progression.
- To assess the combined predictive power of genetic, cerebrospinal fluid (CSF), neuroimaging, and cognitive data.
- To determine optimal markers for identifying individuals at high risk of converting to Alzheimer's disease.
Main Methods:
- A cohort of 85 patients with amnestic MCI was analyzed.
- Baseline measurements included APOE epsilon4 allele, CSF proteins (Abeta(1-42), tau, p-tau(181p)), FDG-PET, hippocampal volume, and episodic memory.
- Predictor variables were classified as normal or abnormal using established cutoffs.
Main Results:
- The annual conversion rate from MCI to AD was 17.2%.
- Abnormal FDG-PET and episodic memory results significantly increased the likelihood of AD conversion (11.7-fold).
- The CSF ratio p-tau(181p)/Abeta(1-42) and FDG-PET predicted cognitive decline.
Conclusions:
- FDG-PET and episodic memory are strong predictors of conversion from MCI to AD.
- CSF biomarkers (p-tau(181p)/Abeta(1-42)) and FDG-PET predict longitudinal cognitive decline.
- Combining these biomarkers can enhance patient selection for clinical trials and identify those likely to benefit from therapies.
More Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
Related Concept Videos
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.